A Real-Life Study Assessing Safety Profile of Biosimilar Adalimumab in Patients with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).
Phase of Trial: Phase IV
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Rheumatoid arthritis
- Focus Adverse reactions
- 06 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism.